Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer
Dr. Kueenburg, former Clinical Development Lead at Celgene, a Bristol Myers Squibb Company, to advance clinical development of mocravimod in Acute Myeloid Leukemia patients undergoing allogeneic hematopoietic stem cell transplant DUBLIN, Nov. 25, 2021 -... Biopharmaceuticals, Oncology, Personnel Priothera, mocravimod, sphingosine, Acute Myeloid Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 25, 2021 Category: Pharmaceuticals Source Type: news

Venetoclax Shows Promise as AML Treatment Option Venetoclax Shows Promise as AML Treatment Option
Venetoclax treatment combinations show benefit as first-line and follow-up therapy for adults with acute myeloid leukemia and for patients who relapse after receiving allogeneic stem cell transplants.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Remarkable' Results in Pediatric Acute Promyelocytic Leukemia'Remarkable' Results in Pediatric Acute Promyelocytic Leukemia
' We felt we owed it to children'to find a less toxic approach, say NCI researchers, who report'radically different'results with a new regimen.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Invasive pulmonary aspergillosis caused by Aspergillus terreus diagnosed using virtual bronchoscopic navigation and endobronchial ultrasonography with guide sheath and successfully treated with liposomal amphotericin B
Invasive aspergillosis is a significant cause of mortality in patients with hematological malignancy. Early diagnosis of invasive pulmonary aspergillosis (IPA) by bronchoscopy is recommended but is often difficult to perform because of small lesion size and bleeding risk due to thrombocytopenia. A 71-year-old woman had received initial induction therapy for acute myeloid leukemia. On day 22 of chemotherapy, she had a high fever, and the chest computed tomography scan revealed a 20-mm-sized nodule with a halo sign. Bronchoscopy assisted by virtual bronchoscopic navigation (VBN) and endobronchial ultrasonography with a guide...
Source: Current Awareness Service for Health (CASH) - November 12, 2021 Category: Consumer Health News Source Type: news

Drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy
NIH-funded clinical trial shows conventional chemotherapy can be avoided in some kids. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - November 10, 2021 Category: American Health Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline du...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 1, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Courage of the little girl in a lockdown that lasted FOUR years
Isolation has been a way of life for Rachel and her family - husband Pete and daughters Suki and Betsie - who began their own lockdown in 2017.due to Suki's acute lymphoblastic leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - September 28, 2021 Category: Consumer Health News Source Type: news

Heartwarming moment four-year-old girl who beat leukaemia rings hospital bell
Daisy Byles, from Lowestoft in Suffolk, was diagnosed with acute lymphoblastic leukaemia in June 2019 after doctors mistakenly thought she was suffering from a cold. (Source: the Mail online | Health)
Source: the Mail online | Health - September 24, 2021 Category: Consumer Health News Source Type: news

Consumer Health: Childhood cancer
September is Childhood Cancer Awareness Month, which makes this a good time to learn about three of the most common types of cancers in children: acute lymphocytic leukemia, neuroblastoma and pediatric brain tumors. Acute lymphocytic leukemia Acute lymphocytic leukemia is a cancer of the blood and bone marrow. It's the most common type of cancer in children, and treatments result in a good chance for a cure. Acute lymphocytic leukemia also can occur in adults, though… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 6, 2021 Category: Databases & Libraries Source Type: news

'Symptoms were things you would see in a normal baby' Ashley Cain issues advice to parents
ASHLEY CAIN and Safiyya Vorajee spoke poignantly about the loss of their child Azaylia to acute myeloid leukemia on ITV'S Lorraine on Tuesday. Ashley issued important advice about the symptoms to spot in your child. (Source: Daily Express - Health)
Source: Daily Express - Health - August 31, 2021 Category: Consumer Health News Source Type: news

New Therapies Have Transformed Acute Lymphoblastic Leukemia Care New Therapies Have Transformed Acute Lymphoblastic Leukemia Care
Novel, chemotherapy-free regimens are poised to become standard of care in Philadelphia chromosome-positive acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 27, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Pharma built on Shire's old cancer business gets new FDA approval
Servier Pharmaceuticals, the Boston-based subsidiary of the French Servier Group that was built around Shire plc ’s cancer business, has scored an approval from the U.S. Food and Drug Administration for a cancer drug and a related diagnostic test. The FDA on Wednesday gave the go-ahead to a drug called Tibsovo, which is currently only used to treat a specific type of acute myeloid leukemia, to be used in a mutation-specific metastatic cholangiocarcinoma, a rare but aggressive cancer that attacks… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 26, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

Why giving blood could help save cancer patients
Melody, 44, had suspected that her son Andrew Berthoud had chickenpox. It was acute lymphoblastic leukaemia and he needed chemotherapy and 22 blood transfusions. (Source: the Mail online | Health)
Source: the Mail online | Health - August 9, 2021 Category: Consumer Health News Source Type: news

Better CNS Control in Children With ALL:'Goldilocks' Approach Better CNS Control in Children With ALL:'Goldilocks' Approach
Treatment of central nervous system involvement in pediatric acute lymphoblastic leukemia needs to be based on risk, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 9, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Duration of Maintenance Therapy Studied in Childhood ALL
MONDAY, Aug. 2, 2021 -- For patients with low-risk childhood acute lymphoblastic leukemia, the omission of seven pulses of therapy with vincristine and oral dexamethasone during the second year of maintenance therapy might not worsen treatment... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 2, 2021 Category: Pharmaceuticals Source Type: news

Inotuzumab ozogamicin cost effective for acute lymphoblastic leukaemia in Sweden and Norway
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news

Eliminating RNA-binding protein improves survival in aggressive leukemia
Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer ’s development and significantly increase the likelihood of survival, according to a study in mice led by scientists at theUCLA Jonsson Comprehensive Cancer Center.The research,published today in the journal Leukemia, could aid in the development of targeted therapies for cancers that have high levels of the RNA-binding protein IGF2BP3 — especially acute lymphoblastic and myeloid leukemias that are characterized by chromosomal rearrangements in the mixed lineage leukemia (MLL) gene.In these ML...
Source: UCLA Newsroom: Health Sciences - July 29, 2021 Category: Universities & Medical Training Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Media News - July 21, 2021 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Investor Update - July 21, 2021 Category: Pharmaceuticals Source Type: news

New discoveries reveal how acute myeloid leukemia walks line between growth and cell death
(University of Chicago) Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a study published in Molecular Cell on July 20, 2021. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2021 Category: International Medicine & Public Health Source Type: news

Ficlatuzumab plus chemotherapy may benefit patients with relapsed/refractory AML
(American Association for Cancer Research) The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news

MD Anderson research highlights for July 14, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising combination therapy for acute myeloid leukemia, understanding mechanisms driving resistance to PARP inhibitors, a therapeutic neoantigen vaccine to treat lung cancer, a novel treatment for triple-negative breast cancer and a new understanding of how telomeres may drive inflammatory bowel disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Inhibitory effects of Tomivosertib in acute myeloid leukemia
(Impact Journals LLC) These Oncotarget findings demonstrate that Tomivosertib exhibits potent anti-leukemic properties on AML cells and support the development of clinical translational efforts involving the use of this drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: news

Unraveling the mechanisms that create the individualized metabolism in leukemia
(Kumamoto University) Lysine-specific demethylase 1 (LSD1), an enzyme involved in gene expression, produces individualized metabolism depending on the type of acute myeloid leukemia cells. Cancer cells have a unique ability to metabolize substances differently from normal cells, and this ability is considered to be a promising therapeutic target. New findings may contribute to the safe and effective use of LSD1 inhibitors as potential anticancer agents, and to the development of highly specific treatments for various leukemia types. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 5, 2021 Category: Cancer & Oncology Source Type: news

FDA Approves Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 30, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 30, 2021 Category: Drugs & Pharmacology Source Type: news

Hypomethylating Agents in Children With Relapsed/Refractory AML Hypomethylating Agents in Children With Relapsed/Refractory AML
Hypomethylating agents can serve as a bridge to transplant for children and young adults with relapsed or refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 25, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Scientists uncover new mechanism that enables development of cancer
(UNC Lineberger Comprehensive Cancer Center) Researchers at the University of North Carolina at Chapel Hill have uncovered a mechanism that activates specific genes, leading to the development of cancers. They showed that a mutation that fuses two unrelated genes can promote a process similar to that observed when oil and water are mixed but do not blend together. The process, called liquid-liquid phase separation, can promote cancers such as acute leukemias. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2021 Category: Cancer & Oncology Source Type: news

Incidence Rates of Pediatric Cancers Vary by Race, Ethnicity
Variation seen by single year of age, including lower incidence of acute lymphoblastic leukemia in Blacks, especially at 1 to 7, 16 to 20 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 21, 2021 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Journal, Source Type: news

Reduced-Intensity Transplant Benefits Older Patients With AML Reduced-Intensity Transplant Benefits Older Patients With AML
Results from two large trials show that for older patients with acute myeloid leukemia (AML), survival is improved if they receive reduced-intensity conditioning before transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

MD Anderson research highlights for June 16, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) inf...
Source: EurekAlert! - Cancer - June 16, 2021 Category: Cancer & Oncology Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD)...
Source: Roche Media News - June 11, 2021 Category: Pharmaceuticals Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD)...
Source: Roche Investor Update - June 11, 2021 Category: Pharmaceuticals Source Type: news

1980 to 2017 Saw Improved Survival for Acute Myeloid Leukemia
THURSDAY, June 10, 2021 -- From 1980 to 2017, there was improvement in survival for acute myeloid leukemia (AML) in all age groups, except for those aged≥70 years, according to a study published in the June 15 issue of Cancer. Koji Sasaki,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 10, 2021 Category: Pharmaceuticals Source Type: news

Venetoclax Shows Activity Against T-ALL in Children Venetoclax Shows Activity Against T-ALL in Children
Data from a small retrospective study suggest that venetoclax-based regimens may have activity against relapsed or refractory T-lineage acute lymphoblastic leukemia in children and young adults.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

When cancer cells " put all their eggs in one basket "
(Cold Spring Harbor Laboratory) Normal cells usually have multiple solutions for fixing problems that may arise. But cancer cells may " put all their eggs in one basket, " getting rid of all backup plans and depending on just one solution. CSHL Professor Christopher Vakoc's lab discovered that a particular type of blood cancer, acute myeloid leukemia, came to depend on a single DNA repair method. They developed a drug that shut down the remaining pathway in lab-grown cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 27, 2021 Category: Cancer & Oncology Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Media News)
Source: Roche Media News - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: World Pharma News)
Source: World Pharma News - May 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

From mice to men: Study reveals potential new target for treating acute myeloid leukemia
(AlphaMed Press) A study released in STEM CELLS indicates that blocking transforming growth factor beta 1 (TGFβ1) could improve hematopoiesis in patients with acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 20, 2021 Category: Cancer & Oncology Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Combination therapy achieves high rates of response for patients with ALL
(University of Texas M. D. Anderson Cancer Center) A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news

UAMS Researcher Gets $1.27M for Cancer Study
A researcher with the Winthrop P. Rockefeller Cancer Institute gets a five-year, $1.27 million grant to work toward developing two treatment options for acute myeloid leukemia patients. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - May 11, 2021 Category: American Health Source Type: news

Philip Schofield hails 'big step forward' cancer treatment that's saving lives
A GAME-CHANGING treatment for acute lymphoblastic leukaemia - a rare cancer of the blood cells - has been discovered. Philip Schofield remarked on the findings on ITV's This Morning on Monday. (Source: Daily Express - Health)
Source: Daily Express - Health - May 4, 2021 Category: Consumer Health News Source Type: news

Using personalized medicine to avoid resistance to leukemia treatment
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20. The standard treatment for T-ALL involves heavy chemotherapy procedures, which result in favorable outcomes with an overall survival of 75% after 5 years. (Source: World Pharma News)
Source: World Pharma News - May 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Study finds potential therapeutic target for pediatric acute myeloid leukemia
(Nemours) Researchers have identified a gene expressed in children with acute myeloid leukemia (AML) that could serve as a new immunotherapy treatment target, according to a new study published today in Blood Advances, a journal of the American Society of Hematology. The study, co-authored by researchers with Nemours Children's Health System, outlines the process and potential path for new immunotherapy drugs that improve survival and reduce treatment-related toxicity in children with AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news